We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Diurnal Group Plc | LSE:DNL | London | Ordinary Share | GB00BDB6Q760 | ORD GBP0.05 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 27.30 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
26/3/2021 12:05 | Ching Ching guys Well done all !!!! | s34icknote | |
26/3/2021 12:04 | This is a massive green light for me and my holding will be long term looking for £3 per share or more In the next year | aimmafia | |
26/3/2021 12:04 | Yep let them clear - I would imagine we get ii interest from here | trotterstrading | |
26/3/2021 12:04 | Cannot believe people are selling the news on this. Will be buying more | talk2dubya | |
26/3/2021 12:04 | Agreed. Brokers updates might give a significant leg up. | small crow | |
26/3/2021 12:03 | Profit takers | aimmafia | |
26/3/2021 12:03 | Nice news but someone is dumping into it! | chesty1 | |
26/3/2021 12:02 | Slight sell on news I suspect then another go later | aimmafia | |
26/3/2021 12:01 | Very. Nicely done all. | babbler | |
26/3/2021 12:00 | Feels good when your investment convictions come good? | affc21 | |
26/3/2021 11:59 | RNS IDMDNL RNS Number : 6728T Diurnal Group PLC 26 March 2021 26 March 2021 Diurnal Group plc ("Diurnal" or the "Company") European Medicine Agency issues positive opinion for Diurnal's second product in Europe In preparation for commercial product launch in Europe, Chronocort(R) to be branded as Efmody(R) Commercial launch anticipated in Q3 2021 Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that the Committee for Medicinal Products for Human Use (CHMP), an advisory committee of the European Medicine Agency (EMA), has issued a positive opinion to the European Commission recommending Efmody(R) (hydrocortisone modified-release hard capsules - development name Chronocort(R) ) as treatment of adult and adolescent patients (12 years and older) with the rare condition congenital adrenal hyperplasia (CAH). The formal approval of marketing authorisation from the European Commission is anticipated in June 2021, in accordance with the 67-day timeline following the adoption of the positive opinion by the CHMP, together with a decision on grant of Orphan Drug Status. To facilitate timely commercial availability, Diurnal has already commenced market access activities in its target European territories, with the first commercial launch anticipated in Q3 2021. The Company intends to mirror its strategy for Alkindi(R) (hydrocortisone granules in capsules for opening) by commercialising the product itself in core European markets. Efmody(R) is a preparation of hydrocortisone that has been specifically designed for patients with CAH, an orphan condition caused by deficiency of adrenal enzymes, most commonly 21-hydroxylase. Approximately two-thirds of CAH patients are estimated to have poor disease control, leading to elevated androgen levels. The condition is estimated to affect a total of approximately 41,000 patients in Europe. Martin Whitaker, Chief Executive Officer of Diurnal, commented: "We are delighted that the CHMP endorses Efmody(R) as a treatment option for adult and adolescent patients suffering from congenital adrenal hyperplasia. We look forward to expanding our commercial portfolio with the planned launch of Efmody(R) across Europe alongside our first product Alkindi(R) , to provide life-long treatment for patients with congenital adrenal hyperplasia, enabling Diurnal to continue to drive towards becoming a world-leading specialty endocrinology business." This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR). For further information, please visit www.diurnal.co.uk or contact: +44 (0)20 3727 Diurnal Group plc 1000 Martin Whitaker, Chief Executive Officer Richard Bungay, Chief Financial Officer Panmure Gordon (UK) Limited (Nominated Adviser +44 (0)20 7886 and Sole Broker) 2500 Corporate Finance: Freddy Crossley, Emma Earl Corporate Broking: Rupert Dearden +44 (0)20 3727 FTI Consulting (Media and Investor Relations) 1000 Simon Conway Victoria Foster Mitchell Notes to Editors About Congenital Adrenal Hyperplasia | dafad | |
26/3/2021 11:59 | To facilitate timely commercial availability, Diurnal has already commenced market access activities in its target European territories, with the first commercial launch anticipated in Q3 2021. | parob | |
26/3/2021 11:59 | Is this boom time? | aimmafia | |
26/3/2021 11:58 | Hopefully you're happy now?Patience, been saying it for months. | mufprat | |
26/3/2021 11:58 | There it is. | small crow | |
26/3/2021 11:55 | I'm expecting £1 to break in the next hour | aimmafia | |
26/3/2021 11:54 | Wider market not even aware of this yet.Looking forward to the RNS! | parob | |
26/3/2021 11:54 | Pretty much nails on P3 US partner and completely derisks the business. IMHO it is now very reasonable to believe DNL will be acquired by a large pharma Co within 2 years for a massive premium | trotterstrading | |
26/3/2021 11:53 | "£3 in 12 months with positive DITEST update" Or TO at £2 long before that? | small crow | |
26/3/2021 11:53 | Yes, I was just wondering when and if to add to my holding. | rafboy | |
26/3/2021 11:50 | The key is,the platform is viable. | geraldus | |
26/3/2021 11:48 | How many other stocks on aim have to regulatory approved drugs... | shrewdmole | |
26/3/2021 11:48 | Depends how long you want to hold Raf by £1.50 minimum short term IMHO. £3 in 12 months with positive DITEST update | trotterstrading | |
26/3/2021 11:48 | Just the start this should trigger a phase 3 partner for US approval and an upfront payment. | shrewdmole | |
26/3/2021 11:47 | Well done all!!!! | trotterstrading |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions